Covid 19 Research using Clinical Trials (Home Page)
COVID-19 RT-PCRWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (8)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug124 | Biosensor Wiki | 0.58 |
| drug688 | Recombinant novel coronavirus vaccine (Adenovirus type 5 vector) Wiki | 0.58 |
| drug19 | 40ml blood sample Wiki | 0.58 |
| drug517 | Montelukast Oral Granules Wiki | 0.58 |
| drug975 | lung ultrasound Wiki | 0.58 |
| drug808 | Symptoms questionnare Wiki | 0.58 |
| drug152 | COVID-19 Serology Wiki | 0.41 |
| drug616 | Placebo Wiki | 0.06 |
There are 3 clinical trials
Clinical Trials
1 Evaluation of the Immune Response in Symptomatic and Asymptomatic Patients' Diagnosed Witih COVID-19
The 2019-20 coronavirus disease, caused by COVID-19, is an ongoing pandemic. The measures in which public health officials quarantine confirmed and isolate symptomatic cases in order to reduce the spread COVID-19 is the common practice used in most countries. However, a significant question remains in regards to the asymptomatically infected individuals, which may propagate the virus and impede infection control. The other question to consider is whether these asymptomatic carriers develop an immune response or continue viral shedding. The purpose of the current study is the evaluate the immune response, i.e developing anti-SARS-CoV-2 antibodies in the asymptomatic cases, in a household study design. We plan to evaluate over 1000 patients with positive COVID-19 results and their households.
NCT04348422 COVID-19 Diagnostic Test: COVID-19 RT-PCR Diagnostic Test: COVID-19 Serology Other: Symptoms questionnare
Primary Outcomes
Description: The percentage of symptomatic patients who developed either IgM/IgG/IgA response within 100 days from COVID-19 Infection
Measure: Proportion of symptomatic patients with immune response (IgM/IgG/IgA) Time: 100 daysDescription: The percentage of Asymptomatic patients who developed either IgM/IgG/IgA response within 100 days from COVID-19 Infection
Measure: Proportion of Asymptomatic patients with immune response (IgM/IgG/IgA) Time: 100 daysSecondary Outcomes
Description: the mean time patients devleoped IgM
Measure: Time to IgM Time: Evaluated within a 100 days followupDescription: the mean time patients devleoped IgG
Measure: Time to IgG Time: Evaluated within a 100 days followupDescription: the mean time patients devleoped IgG
Measure: Time to IgA Time: Evaluated within a 100 days followupDescription: Cohen's kappa coefficient calculated between the different serology kits used for evaluation
Measure: Serology kits inter-observer agreement Time: Evaluated within a 100 days followup2 Rapid Detection of COVID-19 by Portable and Connected Biosensor : Biological Proof of Concept
The objective of study is to estimate the sensitivity and specificity of the COR-DIAL based on nasopharyngeal samples taken at the patient's admission in relation to the final diagnosis of COVID-19 made by the medical team.
NCT04367142 Sars-CoV2 Diagnostic Test: COVID-19 RT-PCR Diagnostic Test: Biosensor
Primary Outcomes
Measure: Sensitivity and specificity of the COR-DIAL based on nasopharyngeal swabs taken on admission of the patient compared to the final diagnosis of COVID-19 made by the medical team Time: Baseline (at admission)Secondary Outcomes
Measure: Cohen's Kappa Coefficient for concordance for the diagnosis of CoV-2-SARS between PCR and COR-DIAL based on nasopharyngeal swabs taken on patient admission Time: Baseline (at admission)3 Use of Lung Ultrasound in Patients Suspected of COVID-19 Infection in the Emergency Room
Covid-19 (English acronym meaning coronavirus disease 2019) is an emerging infectious disease caused by a strain of coronavirus called SARS-CoV-2. The current pandemic has resulted in a significant number of admissions in the emergency room (ER) due to suspicion of COVID-19 infection. Use of lung ultrasound is standard practice to diagnose acute respiratory failure in ER. Recently, typical lung ultrasonographic characteristics of COVID-19 disease has been described. During the COVID-19 pandemic, the use of this tool could be of interest in order to allow an early, simple and reliable triage in patients with suspected COVID-19 infection admitted in ER. In addition, the visualization of early signs in specific areas could be a predictive marker of the severity of the disease. The objective of this project will be to study the association between the signs on lung ultrasound and the result of RT-PCR in patients with suspected COVID-19 infection in the ER.
NCT04368338 Covid-19 Lung Ultrasound Respiratory Complication Diagnostic Test: COVID-19 RT-PCR Procedure: lung ultrasound
Primary Outcomes
Description: Polymerase chain reaction tests after reverse transcription for the detection of covid-19 viral RNA will be done as biological test.
Measure: Lung ultrasound/biological correlation research modulating the severity of Covid-19 disease Time: 6 months